Peptides DB
Research-centric peptide and protocol reference hub
Study 1 of 8DNSP-11 (Dopamine Neuron Stimulating Peptide-11) literaturePubMed · Observational · Preclinical2014

Dynamic changes in dopamine neuron function after DNSP-11 treatment: effects in vivo and increased ERK 1/2 phosphorylation in vitro.

DNSP-11 treatment increased potassium-evoked dopamine release in specific striatal regions at 2 weeks, but overall dopamine release was not significantly altered.

Read at PubMedAdd to compare

Where it sits

this study against the rest of the dnsp-11 (dopamine neuron stimulating peptide-11) corpus
1
Preclinical
7
Observational · this one
0
Open-label
0
Randomised
0
Reviews

Summary and findings

This study investigated the effects of a single treatment of dopamine neuron stimulating peptide-11 (DNSP-11) on dopamine neuron function in rats. The treatment was administered to the substantia nigra, and effects on dopamine release were assessed at 1, 2, and 4 weeks post-treatment. No significant changes in dopamine release were observed, although potassium-evoked release increased in specific striatal subregions at 2 weeks.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.Preclinical2014

Abstract

The authors’ words, as PubMed supplied them

Glial cell-line derived neurotrophic factor (GDNF) has demonstrated robust effects on dopamine (DA) neuron function and survival. A post-translational processing model of the human GDNF proprotein theorizes the formation of smaller, amidated peptide(s) from the proregion that exhibit neurobiological function, including an 11-amino-acid peptide named dopamine neuron stimulating peptide-11 (DNSP-11). A single treatment of DNSP-11 was delivered to the substantia nigra in the rat to investigate effects on DA-neuron function. Four weeks after treatment, potassium (K+) and D-amphetamine evoked DA release were studied in the striatum using microdialysis. There were no significant changes in DA-release after DNSP-11 treatment determined by microdialysis. Dopamine release was further examined in discrete regions of the striatum using high-speed chronoamperometry at 1-, 2-, and 4-weeks after DNSP-11 treatment. Two weeks after DNSP-11 treatment, potassium-evoked DA release was increased in specific subregions of the striatum. However, spontaneous locomotor activity was unchanged by DNSP-11 treatment. In addition, we show that a single treatment of DNSP-11 in the MN9D dopaminergic neuronal cell line results in phosphorylation of ERK1/2, which suggests a novel cellular mechanism responsible for increases in DA function.

Background

The paper addresses the role of dopamine neurons and their modulation, which is significant in various neurological conditions. Prior research has indicated that dopamine signaling is crucial for motor control and reward processing. Understanding how DNSP-11 affects dopamine neuron function could provide insights into potential therapeutic avenues.

Methods

The study employed both in vivo and in vitro approaches to assess the effects of DNSP-11. The specific population, sample size (n), dose, duration, and primary versus secondary outcome measures were not detailed in the abstract.

Results

Not reported in abstract.

Interpretation

Without specific numeric findings, it is challenging to compare the results with existing literature or to assess clinical significance. The lack of detailed statistical analysis limits the ability to draw firm conclusions about the efficacy of DNSP-11. Confounding factors include the use of rodent models, which may not fully replicate human responses.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.
  • Rodent models may not translate to human outcomes.
  • Lack of detailed statistical analysis in the abstract.

Elsewhere in the DNSP-11 (Dopamine Neuron Stimulating Peptide-11) corpus

BIdentification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease.europepmc · 2011 · Mature GDNF peptide down-regulated in AD patients compared to normal controls.HumanCA synthetic five amino acid propeptide increases dopamine neuron differentiation and neurochemical function.europepmc · 2013 · Approximately 66% increase in extracellular DA levels compared to vehicle.AnimalCDynamic changes in dopamine neuron function after DNSP-11 treatment: effects in vivo and increased ERK 1/2 phosphorylation in vitro.europepmc · 2013 · Not reported in abstract.AnimalCMethodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease.europepmc · 2015 · 300μg DNSP-11 increased dopamine turnover in striatum and substantia nigra in normal rats over 3 weeks.AnimalCMethodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques.europepmc · 2018 · Not reported in abstract.AnimalCSpatial and temporal immunoreactivity in the rat brain using an affinity purified polyclonal antibody to DNSP-11.europepmc · 2019 · Not reported in abstract.Animal